Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways

• Main Authors: Ligang Wang (Author), Ying Wang (Author), Qiqi Xie (Author), Songcheng Xu (Author), Chen Yang (Author), Fei Liu (Author), Yang Liu (Author), Fuwei Wang (Author), Weinan Chen (Author), Jianchun Li (Author), Litao Sun (Author)
• Format: Book
• Published: Elsevier, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

RCC is a malignant tumor arising from the urothelium of renal parenchyma that remains challenging to be treated. In this study, we assessed the anti-tumor effects of Resveratrol liposomes (RES-lips) combined with sorafenib on renal cell carcinoma (RCC) and explored the potential mechanisms underlyin...